Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist-Reference-Cited by-同舟云学术

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

Published:2020-09-10 Issue:23 Volume:63 Page:14530-14559
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Scott James S.¹^ORCID,Moss Thomas A.¹,Balazs Amber²,Barlaam Bernard¹^ORCID,Breed Jason³,Carbajo Rodrigo J.¹,Chiarparin Elisabetta¹^ORCID,Davey Paul R. J.¹,Delpuech Oona¹,Fawell Stephen²,Fisher David I.³,Gagrica Sladjana¹,Gangl Eric T.²,Grebe Tyler²,Greenwood Ryan D.¹,Hande Sudhir²,Hatoum-Mokdad Holia²,Herlihy Kara³,Hughes Samantha¹,Hunt Thomas A.¹,Huynh Hoan²,Janbon Sophie L. M.⁴^ORCID,Johnson Tony¹,Kavanagh Stefan⁵,Klinowska Teresa¹,Lawson Mandy¹,Lister Andrew S.¹,Marden Stacey⁶,McGinnity Dermot F.¹,Morrow Christopher J.¹,Nissink J. Willem M.¹^ORCID,O’Donovan Daniel H.¹^ORCID,Peng Bo²,Polanski Radoslaw³,Stead Darren S.¹,Stokes Stephen¹,Thakur Kumar²,Throner Scott R.²,Tucker Michael J.¹,Varnes Jeffrey²,Wang Haixia²,Wilson David M.¹,Wu Dedong⁶,Wu Ye²,Yang Bin²^ORCID,Yang Wenzhan⁶

Affiliation:

1. Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom

2. Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

3. Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom

4. Early Chemical Development, Pharmaceutical Sciences, R&D, Macclesfield, United Kingdom

5. Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom

6. Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01163

Reference46 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

3. Historical perspective on hormonal therapy of advanced breast cancer

4. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

5. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23

2. Structure–Activity Relationship Study of Tris-Benzamides as Estrogen Receptor Coregulator Binding Modulators;ACS Pharmacology & Translational Science;2024-06-25

3. First Multikilogram Synthesis of the Next-Generation Oral Selective ERα Degrader Camizestrant;Organic Process Research & Development;2024-06-07

4. A Novel Oral Selective Estrogen Receptor Degrader TFX06 Suppresses In Vivo Growth of ESR1 Wild-Type and Mutant Tumors;2024-06-04

5. Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials;The Breast;2024-06